Description:
MRE-269 is an orally available and long-acting prostacyclin receptor agonist prodrug used for the treatment of pulmonary arterial hypertension.
- Molecular Weight: 419.5
- Molecular Formula: C25H29N3O3
Purity: ≥98%
Canonical SMILES:
OC(=O)COCCCCN(C(C)C)c1cnc(c2ccccc2)c(n1)c1ccccc1
InChI:
1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
InChIKey: OJQMKCBWYCWFPU-UHFFFAOYSA-N
- Solubility: Soluble in DMSO
- Appearance: Solid powder
- Application: prostacyclin receptor agonist
- Storage: Store at -20 °C
Synonyms:
MRE-269; MRE269; MRE 269; ACT-333679; ACT 333679; ACT333679. [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid; 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-acetic Acid;
More details are to be found on supplier website
